Merck & Co., Inc: Condylomata Acuminata trials

The registry lists 19 Condylomata Acuminata studies with Merck & Co., Inc as lead sponsor. 0 are open to participants now and 12 have results posted.

Phase 1 1Phase 2 3Phase 3 14No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy, Immunogenicity, and Safety Study of V503 (9-valent Human Papillomavirus [9vHPV] Vaccine) in Japanese Males (V503-064)CompletedNCT04635423Phase 3Results posted
• Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)CompletedNCT03546842Phase 3Results posted
• Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)CompletedNCT03158220Phase 3Results posted
• Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)CompletedNCT01651949Phase 3Results posted
• GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)CompletedNCT01245764Phase 3Results posted
• A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)CompletedNCT01047345Phase 3Results posted
• Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)CompletedNCT00851643Phase 1Results posted
• Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)CompletedNCT00543543Phase 3Results posted
• Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)CompletedNCT00092534Phase 3Results posted
• Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)CompletedNCT00092521Phase 3Results posted
• Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)CompletedNCT00092495Phase 3Results posted
• An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)CompletedNCT00090285Phase 3Results posted
• Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)Active, not recruitingNCT05314023Phase 3
• Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)Active, not recruitingNCT02653118
• A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)CompletedNCT00551187Phase 2
• Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)CompletedNCT00520598Phase 2
• Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED)CompletedNCT00517309Phase 3
• Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003)WithdrawnNCT00365443Phase 2
• Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)CompletedNCT00092482Phase 3